Captis Diagnostics Inc.
Pittsburgh, PA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 4620 Henry St, Pittsburgh, PA 15213, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Captis diagnostics - sbir concept award - development of non-invasive assay for molecular characterization of pediatric… | National Cancer Institute (NIH) | $354,637 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Captis Diagnostics Inc. is a Pittsburgh-based corporate entity registered in SAM.gov, specializing in advanced diagnostic technologies with a focus on developing innovative molecular characterization methods using extracellular vesicle (EV) isolation techniques. As a self-certified small disadvantaged business, the company provides research and development services primarily in the biomedical and diagnostics sectors, concentrating on non-invasive molecular testing platforms for various diseases. The company's technological approach centers on developing proprietary nanoprobe systems that enable rapid, efficient isolation of extracellular vesicles from bodily fluids for comprehensive molecular analysis.
Through its federal contract work, Captis Diagnostics Inc. has demonstrated expertise in Small Business Innovation Research (SBIR) concept awards, specifically within the biomedical research domain. The company was awarded a $354,637 firm fixed price definitive contract from the National Cancer Institute to develop a non-invasive assay for molecular characterization of pediatric low-grade glioma. This contract was part of a total small business set-aside solicitation seeking innovative concepts for pediatric and rare cancer therapies, diagnostics, and preventative strategies, with a specific focus on technical feasibility and proof-of-concept development.
Captis Diagnostics Inc. has secured multiple federal grant awards across various agencies, including the National Center for Advancing Translational Sciences, National Institute on Aging, National Cancer Institute, and Defense Health Agency. These grants totaling approximately $2 million support the development of advanced diagnostic technologies, such as a proprietary Lipid Nanoprobe system for extracellular vesicle isolation from bodily fluids, neuronal EV isolation platforms for neurological disease biomarker detection, and liquid biopsy assays for cancer diagnostics. Specific grant projects include developing technologies for predicting pathological complete response in breast cancer, detecting NTRK gene fusions, isolating neuronal extracellular vesicles from blood plasma, and creating minimally invasive diagnostic tools for various diseases including Alzheimer's, Parkinson's, and different cancer types.
Quick answers
Is Captis Diagnostics Inc. registered in SAM.gov?
Yes. Captis Diagnostics Inc.'s SAM.gov registration is active through September 8, 2027.
What is Captis Diagnostics Inc.'s CAGE code?
Captis Diagnostics Inc.'s CAGE code is 7XB96, and its Unique Entity ID (UEI) is JS3HJ4EHJ9J8.
What is Captis Diagnostics Inc.'s most recent federal award?
Captis Diagnostics Inc.'s most recent federal grant award is Magnetic lipid nanoprobe platform for rapid, highly-efficient, and cost-effective isolation of extracellular vesicles… (R44TR005339), from National Center for Advancing Translational Sciences (NIH), on March 11, 2025.
On GovTribe
See Captis Diagnostics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors